Clinical Trial Update: Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating an anti-CTLA-4 antibody in patients with unresectable or metastatic uveal melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)

Snippet

Sponsor: AHS Cancer Control Alberta | Conditions: Uveal Melanoma | Phase 2 | Status: COMPLETED